Market Scope
The Acute Pancreatitis Market Size was assessed at USD 5.5 billion in 2022 and is expected to increase from USD 5.8 billion in 2023 to USD 8.2 billion by 2030, with a compound annual growth rate (CAGR) of 5.90% during the forecast period (2023 - 2030). We will provide COVID-19 impact analysis with the report, offering an in-depth review following the coronavirus disease outbreak.
Top Boosters and Deterrents
The prevalence of acute pancreatitis across the globe has increased notably in the past few years, in line with the growing gallstone and obesity cases. The World Health Organization reveals that the global prominence of obesity almost tripled from 1975 to 2016, while acute pancreatitis cases were recorded in 17 nations in Europe, ranging from 4.6 to 100 per 100 000 individuals. The highest number of cases was reported in northern and Eastern Europe. Excessive alcohol consumption, significant cases of gallstones and ingested medicines are cited to be the top reasons for the increasing prevalence of acute pancreatitis around the globe.
Rising diagnostics rate combined with the increasing government support also foster market growth to a large extent. Moreover, advancements in biotechnological and pharmaceuticals industries have been favorable for the global industry as well. Intense efforts by researchers to develop effective drugs for the treatment of acute pancreatitis and the increasing funds being granted by authorities in this regard can also benefit the global market in the years to follow.
Renowned players are highly focused on new product launches, and are increasingly boosting their global presence by gaining entry into untapped markets. Various firms are coming together to form alliance, with the prime focus on conducting researches based on the treatment of acute pancreatitis. For instance, in June 2020, Mission Cure Holdings LLC came together with Ariel Precision Medicine Inc. and Path BioAnalytics Inc. to create a research-based alliance to come up with innovative and advanced treatments for acute pancreatitis. The collaboration between the three firms will enable them to facilitate a common objective, which is developing an effective and safe treatment option for the disease.
Market Segmentation
Acute Pancreatitis market share has been carefully studied by MRFR on the basis of segments such as cause, treatment diagnosis and end user.
Depending on cause, the global market caters to alcohol, gallstones, and more. Gallstones own a share of 49.52% in the entire market, on account of the expanding elderly population and the rise in hereditary predispositions.
With respect to treatment diagnosis, the market caters to treatment as well as diagnosis. The treatment-wise categories are nutritional support, intravenous fluid, endoscopic retrograde cholangiopancreatography (ERCP), analgesics, and more. The diagnosis-based segments include laboratory tests and imaging tests.
Hospitals clinics and more are the key end-users in the worldwide industry.
Regional Analysis
The market segmentation, with regard to region, includes Europe, Asia Pacific or APAC, MEA or Middle East Africa and the Americas.
As of 2018, the American market owned a share of 41.05% and can proceed to take the lead during the review timeline. Some of the key growth inducers are the rising cases of gall stones and the notable spike in alcohol consumption among people. High availability of quality and superior healthcare facilities across the US and Canada and the rapidly burgeoning geriatric populace also bolster the market demand in the region. The sharp rise in cases of acute pancreatitis in the region has promoted a higher demand for more effective and advanced diagnostic tests as well as treatment options, for which several players are giving intense efforts to gain the upper hand in the market.
The European market predominantly benefits from the escalating number of chronic disorder cases, rampant demand for disease specific treatment and the rising uptake of newer and innovative technologies in the healthcare industry. The existence of a robust and well-developed healthcare infrastructure paired with the soaring awareness level among patients with regard to pancreatitis could lead the European market to greater heights in the following years.
The extensive market growth in APAC is the result of the rising prominence of pancreatic cancer and the soaring need for effective diagnostic tests as well as treatment. Considering the aggravating scenario in the region, a number of non-profit organizations and government agencies are taking up initiatives to boost the awareness level with regard to acute pancreatitis market insights. Technological developments with respect to treatment and diagnostics are giving rise to efficient solutions, which could translate into substantial gains for the regional market in the years to come.
Renowned Contenders
Some of the renowned contenders profiled in the report are B. Braun Melsungen AG, GNT Pharma Co., Fresenius Kabi USA, Baxter International Inc., Medtronic, Boston Scientific Corporation, CalciMedica, Samsung Bioepis, General Electric Company, SCM Lifescience, and more.
About Market Research Future:
Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.
Contact Us:
Market Research Future (Part of Wantstats Research and Media Private Limited)
99 Hudson Street, 5Th Floor
New York, NY 10013
United States of America
+1 628 258 0071 (US)
+44 2035 002 764 (UK)
Email: [email protected]
Website: https://www.marketresearchfuture.com
